Abstract
Oxidative stress and mitochondrial disturbances are the common and important causative factors of aging, and play an important role in the late onset of sporadic neurodegenerative diseases, including Alzheimer disease (AD). Furthermore, emerging evidence from in vitro and in vivo disease models suggests that oxidative stress and increased vulnerability to induction of mitochondrial permeability transition leads to the pathogenesis of the neurological disorders. Towards the goals of developing effective neuroprotectors, this article describes the synthesis and neuroprotective studies of various derivatives of the naturally occurring alkaloid securinine, based on which a lead compound, allomargaritarine (a diastereomer of margaritarine), was identified as an effective therapeutic for neuroprotection. Allomargaritarine exhibits high antioxidant activity, and has significant mitoprotective effect on cellular models of neurodegeneration.
Keywords: Neurodegenerative diseases, neuroprotection, mitochondria, lipid peroxidation, antioxidant, alkaloids, lactones.
CNS & Neurological Disorders - Drug Targets
Title:Neuroprotective effects of the securinine-analogues: identification of Allomargaritarine as a lead compound
Volume: 15 Issue: 1
Author(s): Margarita E. Neganova, Sergei G. Klochkov, Svetlana V. Afanasieva, Tatiana P. Serkova, Ekaterina S. Chudinova, Sergei O. Bachurin, V. Prakash Reddy, Gjumrakch Aliev and Elena F. Shevtsova
Affiliation:
Keywords: Neurodegenerative diseases, neuroprotection, mitochondria, lipid peroxidation, antioxidant, alkaloids, lactones.
Abstract: Oxidative stress and mitochondrial disturbances are the common and important causative factors of aging, and play an important role in the late onset of sporadic neurodegenerative diseases, including Alzheimer disease (AD). Furthermore, emerging evidence from in vitro and in vivo disease models suggests that oxidative stress and increased vulnerability to induction of mitochondrial permeability transition leads to the pathogenesis of the neurological disorders. Towards the goals of developing effective neuroprotectors, this article describes the synthesis and neuroprotective studies of various derivatives of the naturally occurring alkaloid securinine, based on which a lead compound, allomargaritarine (a diastereomer of margaritarine), was identified as an effective therapeutic for neuroprotection. Allomargaritarine exhibits high antioxidant activity, and has significant mitoprotective effect on cellular models of neurodegeneration.
Export Options
About this article
Cite this article as:
Neganova E. Margarita, Klochkov G. Sergei, Afanasieva V. Svetlana, Serkova P. Tatiana, Chudinova S. Ekaterina, Bachurin O. Sergei, Reddy Prakash V., Aliev Gjumrakch and Shevtsova F. Elena, Neuroprotective effects of the securinine-analogues: identification of Allomargaritarine as a lead compound, CNS & Neurological Disorders - Drug Targets 2016; 15 (1) . https://dx.doi.org/10.2174/1871527314666150821111812
DOI https://dx.doi.org/10.2174/1871527314666150821111812 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Blood-Brain Barrier P450 Enzymes and Multidrug Transporters in Drug Resistance: A Synergistic Role in Neurological Diseases
Current Drug Metabolism Challenging the Evidence Based Medicine Principles Among Clinical Obesity Treatments
Current Clinical Pharmacology Factor VIII Levels are Associated with Ischemic Stroke, Stroke Subtypes and Neurological Worsening
Current Neurovascular Research Meet Our Editor:
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Mitochondrial Triglyceride Transfer Protein Inhibition: New Achievements in the Treatment of Dyslipidemias
Current Pharmaceutical Design Glucose Control and Use of Continuous Glucose Monitoring in the Intensive Care Unit: A Critical Review
Current Diabetes Reviews Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Cyclopropyl Scaffold: A Generalist for Marketed Drugs
Mini-Reviews in Medicinal Chemistry Hypertension in Pregnancy: Pathophysiology & Management Strategies
Current Pharmaceutical Design A Direct Correlation between Red Blood Cell Indices and Cognitive Impairment After Aneurysmal Subarachnoid Hemorrhage (aSAH)
Current Neurovascular Research Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Current Issues in the Use of fMRI-Based Neurofeedback to Relieve Psychiatric Symptoms
Current Pharmaceutical Design Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease
Current Neuropharmacology Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Conference Report: (13th International Congress on Amino Acids, Peptides and Proteins (ICAPP); Neurobiology Symposium, October 5-7, 2013; Galveston TX, USA.)
CNS & Neurological Disorders - Drug Targets A Comparison of Emotional Decoding Abilities in Patients with Amnestic Mild Cognitive Impairment, Very Mild and Mild Alzheimer’s Disease
Current Alzheimer Research Atorvastatin Therapy Lowers Circulating Cholesterol but not Free Radical Activity in Advance of Identifiable Clinical Benefit in the Treatment of Mild-to-Moderate AD
Current Alzheimer Research Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry Chemistry and Biology of Thyrotropin-Releasing Hormone (TRH) and its Analogs
Current Medicinal Chemistry Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design